Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

949P - Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330)


16 Sep 2021


ePoster Display


Tumour Site

Hepatobiliary Cancers


Liangrong Shi


Annals of Oncology (2021) 32 (suppl_5): S818-S828. 10.1016/annonc/annonc677


L. Shi1, C. Zhou1, X. Long2, H. Li1, C. Chen1, C. Peng1, P. Li3, J. Li4, S. Gu5, B. Liang6, W. Liao7

Author affiliations

  • 1 Interventional Radiology Department, Xiangya Hospital of Central South University, 410005 - Changsha/CN
  • 2 Radiology Department, Xiangya Hospital of Central South University, 410005 - Changsha/CN
  • 3 Department Of Radiology, The First Affiliated Hospital, Hunan University of traditional Chinese Medicine, 410208 - Changsha/CN
  • 4 Department Of Interventional Oncology, the First Affiliated Hospital, Sun Yat-Sen University, 510080 - Guangzhou/CN
  • 5 Department Of Interventional Radiology, Hunan Cancer Hospital, 410013 - Changsha/CN
  • 6 Department Of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022 - Wuhan/CN
  • 7 Department Of Radiology, Xiangya Hospital of Central South University, 410005 - Changsha/CN

Abstract 949P


Thermal ablation has been showed to induce immunogenic cell death and enhance the effect of anti-programmed death-1 (PD-1) in preclinical study. The open label phase I/II trial evaluated the safety and efficacy of ablation plus toripalimab (a humanized PD-1 antibody) in patients with advanced hepatocellular carcinoma (HCC). Phase I results on time scheduling, safety and preliminary antitumor activity are reported.


Patients who had advanced HCC after failure of a least one-line systemic therapy were included and randomized into 3 arms. In arm A, patients received toripalimab (240mg, Q3W) as monotherapy. In arm B, patients received subtotal ablation, defined as complete treatment of 1-5 lesions by thermal ablation and leave others lesions intact. Toripalimab (240mg, Q3W) was started on day 3 after ablation. In arm C, patients received toripalimab (240mg, Q3W) on day 14 after ablation.


Forty-eight patients (16 per arm) were included. Seventy five percent of patients experienced treatment-related adverse events (TRAE). The most common TREAs were mild (grade 1/2) and include influenza-like symptoms (25%), AST and/or ALT elevation (22.9%), hypothyroidism (22.9%), hypertension (16.6%), diarrhea (14.6%) and proteinuria (12.5%). Grade 3/4 TRAEs was reported in 18.7% of patients in arm A, 25.0% in arm B and C, respectively. One patient in arm A (6.3%) and one in arm B discontinued toripalimab treatment because of TRAE. No TRAE led to death. By the cutoff date, the objective response rate (ORR) was 18.8% in arm A, 37.5% in arm B and 31.2% in arm C. In arm B, 2 patients (12.5%) achieved complete response (CR). Initiating toripalimab treatment on day 3 after ablation was recommended for phase II evaluation.


The combination of subtotal thermal ablation and toripalimab was tolerable and showed promising antitumor activity in advanced HCC, especially with optimal schedule.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Xiangya Hospital, Central South University.


TopAlliance Biosciences Inc.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.